Get to know our clinical trials
Trial of intratumoral administration of DNX-2401 for the treatment of high-grade, recurrent or refractory brain tumors in pediatric patients or young adults
THE MAIN OBJECTIVE OF THIS TRIAL IS TO ASSESS THE EFFICACY OR ANTITUMOR EFFECT OF A VIRUS CALLED DNX-2401 IN PATIENTS WITH HIGH-GRADE BRAIN TUMORS THAT HAVE RELAPSED OR PROGRESSED AFTER STANDARD TREATMENT.
Cancer Center
Status
In recruitment
headquarters
Pamplona/Madrid
Early phase
Technical Summary
- INTRATUMORAL ADMINISTRATION OF DNX-2401 FOR THE TREATMENT OF HIGH-GRADE, RECURRENT OR REFRACTORY BRAIN TUMORS IN PEDIATRIC PATIENTS OR YOUNG ADULTS
- Code EudraCT: 2024-515009-24-00
- Protocol number: PED-DNX2401
- Promoter: Clinica Universidad de Navarra
- Molecule/Drug: DNX-2401
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.